Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
| 0.051 | |
| 0.051 | |
| - | |
| 0.051 | |
| 0.051 | |
| 0.029-0.52 | |
| 624 K | |
| 12 233 K | |
| 5 640 K | |
| -0.16 | |
| 0.726 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
One reason we invest in the stock market is that we’re all looking to secure our financial futures. We want to be comfortable in our retirements and provide for our families and even future generati...
Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
